William James Garner, a 10% Holder, acquired 20,000,000 Common Shares at a price of $0.15 and 10,000,000 Warrants exercisable at $0.20 on a direct ownership basis through a prospectus or prospectus exempt offering on April 22nd, 2022. This represents a $3,000,000 investment into the company's shares and an account share holdings change of greater than 100%.
TRYP Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
No Comments